Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "TILT[LastUpdatePostDate]SEARCH[Study]AREA[SponsorSearch]Fujian Cancer Hospital"
Count: 133
Selected: 0
NCT04421469Triprilimab(JS001) and Chemotherapy Combined With Local Treatment for Multiple Metastatic NPC
NCT04319471Sufficient Chemotherapy Combine With Maintenance Chemotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma
NCT04220528Radical Radiotherapy and Chemotherapy Combined With Maintenance Chemotherapy in the Treatment of Stage N3 NPC
NCT05839470Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer
NCT05824312HRQOL in Locally Advanced Thyroid Carcinoma
NCT05799443Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer
NCT05319639Phase I Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab
NCT05753826Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With HRD-positive Recurrent Platinum-resistant Ovarian Cancer.
NCT05751265Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric Cancer
NCT05664139Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant Melanoma
NCT05699655Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer
NCT05223088Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer
NCT05675033Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma
NCT05663177Almonertinib Plus Metronomic Oral Vinorelbine
NCT05649618TIL Cells for the Treatment of the Advanced Solid Tumors Patients
NCT05648994TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid Tumors
NCT05640726The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy
NCT05595889Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer
NCT05628610Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer
NCT05624099Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.
NCT05597527Fluzopari Combined With Apatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer
NCT05561023Phase Ⅰa Clinical Study of Hawthorn Red Pigment Combined With Standard Analgesic for Refractory Cancer Pain
NCT05519956Elective Level Ib Irradiation in Nasopharyngeal Carcinoma Patients Based on the International Guidelines
NCT05314101TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer
NCT05497076the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy
NCT05479240Short-range Radiotherapy Sequential Tislelizumab Combined With Chemotherapy Versus Long Range Radiotherapy and Chemotherapy Combined With Tislelizumab Neoadjuvant Therapy for Locally Advanced Rectal Cancer
NCT05335460To Determine the Efficacy and Safety of Envafolimab Combined With XELOX for Locally Advanced Colon Cancer
NCT03666221Nimotuzumab for Recurrent Nasopharyngeal Carcinoma
NCT05266820Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancer
NCT05192681Tislelizumab as Cross-line Treatment for Advanced NSCLC
NCT05007145PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
NCT05131243the Role of ctDNA in Predicting the Recurrence Risk of Colorectal Cancer
NCT04764006Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II Study
NCT05001360Study of FMT Combined With Nivolumab in Gastric Cancer
NCT05035446Short-term Outcomes of SILS+1 Versus CLS for Distal Gastric Cancer
NCT05049811Effects of Mobile Medicine on Cancer Patients
NCT05019690Apatinib Combined With Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer
NCT04955886Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma
NCT04745741Evaluating the Rationality of the International Guideline About Selective Coverage of Level Ib in CTV With NPC
NCT02845908POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel in AGC
NCT04844645Using Mini Program for Self-management VS Conventional Pharmaceutical Care for Cancer Pain
NCT04785768IV PCA With or Without Continuous Dose vs Oral Opioid to Maintain Analgesia for Severe Cancer Pain After Successful Titration
NCT03708536Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal Adenocarcinoma
NCT03639415Change the Dose Frequency of Controlled-Release Oxycodone to Refractory Pain
NCT03380689Phase I Study of Biweekly SIRB Regimen for Metastatic Colorectal Cancer
NCT03375515PCA vs Non-PCA Intravenous Hydromorphone Titration for Severe Cancer Pain
NCT04243954Intravenous vs Oral Analgesia in Cancer Patients With Severe Pain After Successful Titration
NCT04734249Second-line Surufatinib Combined With Chemotherapy in Advanced CRC
NCT04613804Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy
NCT04387266To Evaluate the Efficacy and Feasibility of Modified Reduce-volume Target IMRT in the Treatment of Patients With Non-metastatic NPC